Ex­sci­en­tia ter­mi­nates Bay­er pact half a year ear­ly, col­lect­ing small por­tion of €240M promised

Bay­er and Ex­sci­en­tia are wind­ing down their three-year col­lab­o­ra­tion, leav­ing the big Ger­man phar­ma to take the AI-de­signed com­pounds born out of the pact fur­ther.

Lon­don-based Ex­sci­en­tia re­vealed in its Q2 up­date that the part­ners have “mu­tu­al­ly agreed to end” their col­lab­o­ra­tion, which kicked off in ear­ly 2020, af­ter re­cent­ly achiev­ing a drug dis­cov­ery mile­stone. In an SEC fil­ing, Ex­sci­en­tia said it ter­mi­nat­ed the pact on May 30, about six months ear­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER